Cochrane · systematic review · CD008907
Eslicarbazepine acetate add‐on therapy for drug‐resistant focal epilepsy
Chang, X-C, Yuan, H, Wang, Y, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 6 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsEslicarbazepine acetate add‐on for drug‐resistant focal epilepsy
Population: people with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
≥ 50% reduction in seizure frequency (adults) | RR 1.71 [1.42, 2.05] | 5 studies · 1799 participants | Moderate Downgraded: risk of bias, inconsistency |
≥ 50% reduction in seizure frequency (children aged 6–18 years) | RR 1.35 [0.98, 1.87] | 2 studies · 322 participants | Moderate Downgraded: risk of bias |
Freedom from seizures | RR 3.16 [1.73, 5.78] | 6 studies · 1922 participants | Moderate Downgraded: risk of bias |
Treatment withdrawal (any reason) | RR 1.25 [0.93, 1.7] | 7 studies · 2185 participants | Moderate Downgraded: risk of bias |
Treatment withdrawal (adverse effect) | RR 2.72 [1.66, 4.46] | 7 studies · 2185 participants | Moderate Downgraded: risk of bias |
Adverse effects | no estimate extracted | NR | Moderate Downgraded: risk of bias |